Literature DB >> 33565349

Ricinus communis Butanol Fraction Inhibits MCF-7 Breast Cancer Cell Migration, Adhesion, and Invasiveness.

Rixile Mabasa1, Kholofelo Malemela1, Karabo Serala1, Mante Kgakishe1, Thabe Matsebatlela1, Matlou Mokgotho1, Vusi Mbazima1.   

Abstract

In this study, the potential of an n-butanol fraction from Ricinus communis to prevent metastasis in MCF-7 breast cancer cells was investigated. The effect of the fraction on BUD-8 and MCF-7 cell viability was assessed using the MTT assay. Apoptotic cell death was analyzed by Hoechst staining assay. The antimetastatic effect of the fraction on MCF-7 cell was evaluated using the wound healing, adhesion and Boyden chamber invasion assays. Gelatin-zymography was used to assess the effect of the fraction on MMP-2 and MMP-9 activity. The expression profile of proteins implicated in metastasis and angiogenesis was determined using the human angiogenesis antibody array kit, following treatment with the fraction. BUD-8 cell viability was significantly reduced at concentrations between 300 and 500 µg/ml of the extract. In contrast, a significant reduction in cell viability was seen in MCF-7 cells treated with 400 to 500 µg/ml of the fraction. At sub-lethal concentrations (100 and 200 µg/ml) of the fraction, no nuclei morphological changes associated with apoptotic cell death were observed in MCF-7 cells. In addition, the fraction showed to have an inhibitory effect on MCF-7 cell migration, adhesion, invasiveness, and MMP-2 activity. Moreover, the fraction was seen to modulate the expression of several proteins, such as MMP-9, uPA, VEGF, and TGF-β1, playing a role in the metastasis process. This study demonstrates that the n-butanol fraction of R. communis can inhibit major steps of the metastatic cascade and modulate metastasis regulatory proteins. Thus, the fraction can be considered a potential source of antimetastatic agents that could be useful in the treatment of malignant cancers.

Entities:  

Keywords:  MMPs; Ricinus communis; anti-invasivessnes; antiangiogenesis; antimetastasis

Year:  2021        PMID: 33565349     DOI: 10.1177/1534735420977684

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  1 in total

1.  Matteucinol combined with temozolomide inhibits glioblastoma proliferation, invasion, and progression: an in vitro, in silico, and in vivo study.

Authors:  J B Netto; E S A Melo; A G S Oliveira; L R Sousa; L R Santiago; D M Santos; R C R Chagas; A S Gonçalves; R G Thomé; H B Santos; R M Reis; R I M A Ribeiro
Journal:  Braz J Med Biol Res       Date:  2022-08-22       Impact factor: 2.904

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.